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Abstract
Background: High-grade gliomas are amongst the most deadly human tumors. Treatment results are disappointing. Still, in
several trials around 20% of patients respond to therapy. To date, diagnostic strategies to identify patients that will profit
from a specific therapy do not exist.
Methods: In this study, we used serum-free short-term treated in vitro cell cultures to predict treatment response in vitro.
This approach allowed us (a) to enrich specimens for brain tumor initiating cells and (b) to confront cells with a therapeutic
agent before expression profiling.
Results: As a proof of principle we analyzed gene expression in 18 short-term serum-free cultures of high-grade gliomas
enhanced for brain tumor initiating cells (BTIC) before and after in vitro treatment with the tyrosine kinase inhibitor
Sunitinib. Profiles from treated progenitor cells allowed to predict therapy-induced impairment of proliferation in vitro.
Conclusion: For the tyrosine kinase inhibitor Sunitinib used in this dataset, the approach revealed additional predictive
information in comparison to the evaluation of classical signaling analysis.
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Introduction
High-grade gliomas include the most frequent type of primary
central nervous system (CNS) tumors, glioblastoma (GBM) [1].
GBM show diffuse infiltration of the surrounding brain, making a
curative surgical resection impossible. Moreover, GBM are
molecularly heterogeneous. Consequently, the clinical manage-
ment of GBM is challenging and outcomes are poor with a median
survival time of only 14.6 months [2], and only rare long-term
survivors [3].
Sunitinib is a small-molecule inhibitor (SMI) with antiangio-
genic and antitumor activity mediated through inhibition of
multiple receptor tyrosine kinases (RTKs). Sunitinib is FDA-
approved for the first-line treatment of advanced renal cell
carcinomas and progressive gastrointestinal stromal tumors (GIST)
resistant to Imantinib [4,5]. Interestingly, Sunitinib shrinks renal
cell carcinoma CNS metastasis in the brain [6], suggesting that it
crosses the blood-brain-barrier (BBB). The prevalent VEGF
receptors 1–3 and platelet derived growth factor receptor
(PDGFR) a/b are targets of Sunitinib [7]. Their role in GBM
growth and neovascularisation has been widely studied [8,9]. In
preclinical studies using in vitro models of primary CNS tumors
Sunitinib inhibited proliferation and migration [10–14]. Particu-
larly in GBM models, Sunitinib alone [15] or in combination with
radiation therapy [16] showed potent antiangiogenic and anti-
invasive effects. Clinical trials of Sunitinib and other small-
molecule inhibitors targeting RTKs have however shown a clinical
response only in subgroups [1,17,18] of GBM patients. Disap-
pointingly, the amplification and mutation status of the targeted
receptors alone are not predictive for response [1,18].
The cancer stem cell hypothesis postulates that clones of
pluripotent cells exerting stem cell like properties [19,20] induce
tumors and maintain the tumor bulk. This would make them the
primary targets of treatment [21]. Brain tumor initiating cells
(BTICs) are propagated under serum-free conditions, undergo
sustained self-renewal and retain tumorigenic potential forming
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tumors that recapitulate the phenotypes of parental tumors [22–
25]. Existing literature suggests that this subpopulation of tumor
cells holding stem-cell like features contribute to chemotherapy
resistance [26]. Regarding response to radiation conflicting results
have been reported [27,28]. Consequently, these cells might hold
relevant information for predicting therapy response.
Today, treatment decisions for GBM patients are based on age,
performance status [29], and increasingly on molecular markers
like MGMT promoter methylation. Recent genomic studies
established sub-classifications of GBMs based on gene expression
profiling [30,31] or integrated genetic and epigenetic profiling
[32]. These GBM subtypes were associated with distinct prognosis
and benefit from classical chemo-radiotherapy. No specific
treatment selection including novel targeted agents can be derived
from these classifications.
Here, we suggest to use expression profiles of in vitro treated
tumor cell cultures to predict treatment response. As a first
development step towards this approach, we treated 18 short-term
cultures of high-grade gliomas with Sunitinib. To sharpen
predictive expression patterns we enriched specimens for brain
tumor initiating cells (BTIC). From these specimens we generated
expression profiles before and 6 hours after treatment, and
signatures for treatment response were constructed to predict
in vitro proliferation and migration after treatment.
Materials and Methods
Tumor samples and patient characteristics
Native glioma tissue samples were obtained from patients
undergoing surgical resection at the local Department of
Neurosurgery with a diagnosis of high-grade glioma WHO grade
III or IV. All tumors were histologically classified according to the
2007 WHO classification of tumors of the central nervous system
by the local neuropathologist (MJR). Specimens were cultured
according to current criteria for the culture of brain tumor
initiating cells (BTIC) [22]. In addition to conventional histology,
GFAP and IDH1 (R132H) immunoreactivity as well as MGMT
promoter methylation (by methylation specific PCR) were assessed
in the primary operation material, and the same parameters plus
Nestin (by Western blot) were repeated in the short-term BTIC
cultures. Clinical data of all patients were followed until disease
progression, and overall survival was evaluated using the RANO
criteria [33]. All patients gave written informed consent, and this
study and further use of the samples were specifically approved by
the ethics committee of the University of Regensburg, Regens-
burg, Germany (Nou 11-103-0182).
Primary cell culture of brain tumor initiating cells (BTICs)
Tissue samples were kept in PBS at 4uC and processed within
24 hours after surgery. Samples were mechanically dissociated
using a scalpel followed by aspiration through a Pasteur pipette. If
cells did not dissociate spontaneously, enzymatic dissociation with
1% Trypsin/EDTA at 37uC for 5 minutes maximum was
performed. After washing with PBS, cells were passed through a
cell strainer with 30 mm pore size to obtain a single cell suspension
(Merck Millipore, Darmstadt, Germany). Remaining tumor cells
were cultured in stem-cell permissive RHB-A media (Stem Cell,
Cambridge, UK) supplemented with 20 ng/ml of each human
recombinant epidermal growth factor (EGF; R&D Systems,
Minneapolis, USA) and human recombinant basic fibroblast
growth factor (FGF; Peprotech, Hamburg, Germany). Culture
media were replaced by fresh media with the indicated supple-
ments twice a week. Under these in vitro conditions BTIC
specimen grew either as spheres or exhibited adherent growth
spontaneously (Table S1). To verify tumor-initiating capacities of
our BTIC primary samples, some cultures were transplanted
orthotopically in immunocompromised mice (data not shown). In
addition, stem cell marker expression was documented by
immunohistochemical staining for Nestin and Sox2 and flow
cytometry analysis of CD133 expression (partly presented in Table
S1). Differentiation capacity was confirmed by immunohistochem-
ical staining for differentiation markers of specific neural lineages
(GFAP, GalC, bIII-Tubulin) after cultivation in 10% FCS for 14
days (not shown). Clonogenicity was tested in a 96-well single cell
dilution assay (not shown). The lowest available passage of all
BTIC primary cultures (usually below passage 8) was used for all
assays.
Treatment of BTIC cultures with Sunitinib
Sunitinib was purchased from Sigma Aldrich (St. Louis,
Missouri, USA) and prepared as a 25 mmol/l stock solution in
aliquots of 0.5 ml in DMSO for in vitro studies. BTICs were
grown in cell culture dishes (TPP, Trasadingen, Switzerland) until
they formed a subconfluent monolayer (density of 80%). Laminin
coated dishes were used for cells that grew non-adherent under
stem cells conditions (Table S1). Before treatment, cells were
cultured in growth factor free medium for 16 hours to simulate
in vivo conditions. After starvation, cells were treated with 1 mM
Sunitinib in the treatment groups or 0.00025% DMSO in the
control groups either with or without supplementation of
recombinant growth factors PDGF-A/B and VEGFA (25 ng/ml)
for 6 hours before harvest. Each treatment combination was set up
twice. Cells were either harvested in RLT-lysis buffer (provided in
the RNeasy Kit, Qiagen, Hilden, Germany) for subsequent RNA-
extraction or in lysis buffer (25 mM Tris, 150 mM NaCl, 5 mM
EDTA, 10% Glycerol, 1% Triton X100, 10 mM Na-Pyropho-
sphat, 1 mM Na-Orthovanadate, 10 mM Glycerol phosphate) for
whole cell protein extraction.
Microarray analysis
Hybridization to arrays was performed in the local Competence
Center for Fluorescent Bioanalytics. Quality of RNA was
confirmed by HPLC and RNA was further processed by reverse
transcription. cDNA was converted to Biotin-labeled cRNA which
was the hybridized to Affymetrix hugene.1.1.st GeneChips
(Affymetrix, Santa Clara, California, USA). Data are deposited
at the gene expression omnibus (GEO) functional genomics data
repository under accession number GSE51305.
RT- and Quantitative PCR
First-strand specific cDNAs were generated by using the reverse
transcription kit (Promega, Madison, USA). Quantification of
mRNA expression was performed by real-time PCR (Mx3000P
Quantitative PCR [qPCR] System, Stratagene, Germany) using
the Brilliant III Ultra-Fast SYBR Green QPCR Ultra fast Master
mix (Agilent Technologies, Santa Clara, California, USA). A
standard curve with serially diluted cDNA was prepared for the
target gene and reference gene (b-Actin). Primer sequences are
listed in the supplementary section (Table S2).
Western blot analysis
For Western blot analysis, 15 to 20 mg of total cell lysates were
diluted in 15 ml of Laemmli buffer, separated on a 10% SDS-
PAGE gel and transferred to nitrocellulose membranes by semi-
dry blotting. The membranes were blocked with 5% milk powder
in 0.02% Tween TBS (TBST) for 1 hour. Based on previous
results on key molecules regulated by Sunitinib (Pfizer, investiga-
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tors brochure, March 2008), membranes were incubated with
antibodies against Akt, phospho-Akt (Ser473), STAT3, Phospho-
STAT3 (Tyr705) (all from Cell Signaling, Danvers, USA), ERK1/
2, phospho-ERK1 (T202/Y204)/ERK2 (T185/Y187) (all from
R&D Systems, Minneapolis, USA), and b-Actin (Sigma Aldrich,
Missouri, USA) or GAPDH (Santa Cruz Biotechnology, Heidel-
berg, Germany) overnight at 4uC. Bound antibodies were
visualized with a horseradish peroxidase–linked antibody against
mouse or antibody against rabbit immunoglobulin G (R&D
Systems, Minneapolise, USA) followed by enhanced chemilumi-
nescence reaction (Roche Applied Science, Basel, Switzerland).
Western blots were repeated three times.
Proliferation assay
BTICs were grown in a 96-multiwell plate and treated with
1 mM Sunitinib in the treatment group or 0.00025% DMSO in
the control group, diluted in stem cell media supplemented with
PDGF-A/B and VEGFA (each 25 ng/ml) for indicated times.
Non-adherent cells were seeded on Laminin-coated wells. XTT
Reagent was added to the media 4 hours prior to the photometric
measurement, and cellular viability was assessed by the Cell
Proliferation Kit II (XTT) from Roche Applied Science (Roche,
Basel, Germany) according to the manufactures protocol. Photo-
metric evaluation was performed with the Varioscan ELISA
reader (Thermo Scientific, Massachusetts, USA). For every
individual BTIC line the XTT assay was repeated at least three
times. Proliferation rates were calculated for each treatment, and
values were prepared for correlation analysis to microarray and
other data performed by bioinformatics as described below.
Migration assay
The formation of round-shaped aggregates of BTIC cells
in vitro typically occurs in a non-adherent microenvironment.
Therefore, so called multicellular tumor spheroids were generated
by plating 100 ml of a single cell suspension (3–56104/ml) on an
agar-coated well. Mature spheroids with a mean area of 0.45 mm2
were explanted to round-bottom 96-well plates containing the
corresponding treatment (1 mM Sunitinib in the treatment group
or 0.00025% DMSO in the control group) diluted in stem cell
media supplemented with 25 ng/ml of the recombinant growth
factors VEGFA and PDGF-A/B. Transferred spheroids were
monitored using a light microscope. Cells were allowed to migrate
from the spheroid surface for 16 hours. Spheroid areas were
measured using the ImageJ Software (NIH, Bethesda, USA), and
spreading of surfaces was evaluated in 8 spheroids of each
treatment group. Median surface areas were calculated for each
treatment, and absolute levels of expansion were recorded. For
further correlation analysis spheroid areas were corrected for size
differences at time point zero.
Computational Analysis and Statistics
Computational analysis was performed using R and Biocon-
ductor (http://www.bioconductor.org). Expression values were
corrected and normalized using RMA [34]. To account for the
data structure we compensated for between patient variability in a
pre-processing step using the bioconductor package ComBat [35]
by modeling every patient as a separate ‘‘batch’’ of four samples
(before/after treatment; with/without growth factor). Differential-
ly expressed genes were identified using the package Limma [36].
Limma is based on linear models. We included growth factor
treatment of cell cultures into the models to adjust for its
confounding effect on gene expression. False discovery rates (FDR)
of gene lists were calculated according to Benjamini Hochberg
[37]. Signatures for quantitative prediction of treatment response
were learned using ‘Least Angle Regression’ [38] as implemented
in the bioconductor package LARS. Note that LARS analysis
incorporates the selection of signature genes. Prediction perfor-
mance was validated in leave one out cross validation. Selection of
signature genes was done separately for all left out samples.
If not specified otherwise statistical analysis of in vitro data was
performed using the student’s t-test. A p-value less than 0,05 was
considered to be statistically significant (*, p,0,05; **p,0,01,
***p,0,001).
Results
Characterization of patient material
Eighteen native glioma tissue samples were obtained from
patients undergoing surgical resection at the local Department of
Neurosurgery. Tumors were neuropathologically classified as
GBM in 16 cases, gliosarcoma in 1 case and anaplastic
astrocytoma in another case (Table S1). MGMT promoter
methylation varied from 0 to 100%, and 2 cases were mutated
at the R132H locus. MGMT promotor methylation was followed
in the short-term BTIC cultures (Table S1).
Sunitinib induced modulation of signaling pathways can
be detected for therapeutic dosages of Sunitinib and can
be boosted by supplementary growth factors
Brain tumor initiating cells from high-grade glioma resections
were starved in serum- and growth factor-free medium prior to
treatment. After treatment with various concentrations of
Sunitinib we assessed the activity of potential downstream
signaling cascades by Western blot with or without growth factor
supplementation (Fig. 1A). Growth factor supplementation was
used to examine the inhibition of pre-stimulated pathways.
Growth factor free conditions were chosen to investigate the
blockage of autocrine and paracrine pathway activation. VEGF/
PDGF, but not EGF/bFGF activated signaling was considerably
abolished by Sunitinib. Sufficiently strong responses were observed
when cell cultures were activated with 25 ng/ml PDGF-A/B and
VEGFA and cells remained without further exogenous stimuli
during Sunitinib treatment.
Next, the Sunitinib dosage was calibrated using a concentration
row (Fig. 1B). A concentration of 0.5 mM of Sunitinib was
sufficient to abolish PDGF/VEGF-stimulated activation of AKT
while still lying in the range of concentration measured in tumor
tissue of patients treated with Sunitinib [39,40].
Heterogeneous treatment response is mirrored in
Sunitinib induced modulation of signaling pathways
All 18 BTIC lines were treated with 1 mM of Sunitinib or
0.00025% DMSO as control. Next, phosphorylation of down-
stream signaling molecules of Sunitinib target-RTKs pSTAT3,
pAKT and pERK1/2 were assessed by Western blots (Fig. 1C and
Table 1). Signal intensities in reference to the related unstimulated
samples were evaluated by 3 independent investigators for each
BTIC line yielding semi-quantitative consensus strengths of
response. The response to treatment in vitro was again heteroge-
neous. Phosphorylation status of STAT3 and AKT were lower in
Sunitinib treated cells than in controls in 64% and 70% of
evaluated signals without prior VEGF/PDGF-stimulated activa-
tion. The strength of inhibition varied considerably. Inhibition of
ERK-phosphorylation was observed in only 35% of cases although
and was less pronounced than STAT3 and AKT inhibition
(Fig. 1C and Table 1). Further, the induction potential on the
Response Prediction in Glioma Progenitor Cells
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STAT3, AKT and ERK pathways by VEGF/PDGF differed
considerably.
In summary, we observed heterogeneous responses to Sunitinib
treatment on the levels of pathway activation, signal propagation,
and target protein expression. This result underscores the need to
identify responders prior to treatment.
Sunitinib inhibits proliferation in a subset of cases
We assessed the proliferation of all 18 BTIC lines at several time
points between 24 and 144 hours after Sunitinib treatment by
XTT assays and compared them to control samples observed over
the same time period. Again, different responses were observed
(Fig. 2A, B).
For 60% of the BTIC, treatment for 24 hours had no detectable
effect (data not shown). However, after 96 hours, the number of
viable cells was clearly reduced in responding BTIC lines (Fig. 2B,
p = 0.005). This trend was even more pronounced at later time
points.
Following this preliminary analysis, a 96 hour XTT assay was
repeated at least three times for each BTIC line (Fig. 2C). We
observed inhibition of proliferation of up to 56% in 3 BTIC lines,
whereas 4 lines exhibited no detectable response at all. BrdU
assays were performed for 2 of the BTICs to control for XTT
assay validity yielding similar proliferation inhibition rates as the
XXT assays (Fig. S1). Further we proved that PDGF/VEGF
preserves constant proliferation capacity of BTICs for the analyzed
time span (Fig. S2, p = 0,1). Again the observed heterogeneity
underscores the need to identify responders prior to treatment.
Sunitinib inhibits cellular motility in a subset of cases
A tumor spheroid-based migration assay that simulates tumor
cell dissemination from a solid microtumor [41,42] was used to
investigate tumor cell motility after treatment with 1 uM Sunitinib
or control. In this assay, tumor cells propagate from the spheroid
over the dish surface, and migration rates in terms of an area
covered by radial spreading were measured using area calculation
by ImageJ 16 hours after treatment. A pair of exemplary BTICs in
which migration was differentially inhibited is shown in Fig. 3A.
The relative difference of spreading areas under treatment with
Sunitinib in comparison to control was calculated for each
Figure 1. Phosphorylation pattern of signaling molecules downstream of Sunitinib target receptor tyrosine kinases. Western Blot
analysis was performed with 18 BTIC lines of which 3 representatives are shown. (A) To evaluate distinct phosphorylation patterns under treatment,
BTIC-1 was treated with 1 mM Sunitinib or 0.00025% DMSO for 6 hours with growth factor supplementation (25 ng/ml) as outlined. (B) To evaluate a
dose curve for Sunitinib, BTIC-14 cells were incubated with different Sunitinib-concentrations or 0.001% DMSO in media supplemented with 25 ng/
ml of each VEGFA and PDGF-AB. (C) After definition of growth factor supplementation and Sunitinib dose, Western Blot analysis for changes in
phosphorylation after treatment with Sunitinib was performed with 18 BTIC lines of which 3 representatives are shown. Cells were treated with 1 mM
Sunitinib or 0.00025% DMSO with (+) or without (–) growth factors (GF) PDGF-AB and VEGFA (25 ng/ml) for 6 h after incubation in growth factor free
medium for 16 h. The asterisks (*) indicates the corresponding loading control. GAPDH was used as protein loading control.
doi:10.1371/journal.pone.0108632.g001
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individual BTIC line (Fig. 3B). In line with all previous
observations responses varied substantially across BTIC lines. To
validate these data, we performed wound migration assays in
BTIC cultures. All cultures evaluated with both methods showed
comparable migration inhibition rates (Fig. S3). Interestingly,
inhibition of proliferation and inhibition of migration did not
correlate (Fig. 3C, p= 0.343), suggesting that Sunitinib targets
these phenotypes via distinct signaling pathways. Once more, the
observed heterogeneity underscores the need to identify respond-
ers prior to treatment.
Heterogeneity of signaling pathway activation results
into genome wide expression profiles
Transcriptome wide expression profiles of BTIC enriched cell
cultures were generated before and 6 hours after in vitro
treatment with Sunitinib using Affymetrix hugene.1.1.st Gene-
Chips. RNA samples from Sunitinib treated BTICs were collected
concurrently with protein samples. All 18 BTIC lines were treated
with 1 mM Sunitinib or 0.00025% DMSO with and without the
combination of VEGF and PDGF-AB for 6 hours after overnight
starvation in serum- and growth factor-free medium.
All data analysis was restricted to the 500 genes with the highest
expression variances across all samples. Notably, the expression
differences between BTICs from different patients were stronger
than the differences we observed in the identical cultures before
and after treatment (Fig. S4). In order to zoom in on treatment
effects, we compensated for inter-tumor variability computation-
ally using the batch effect correction algorithm Combat [35].
Fig. 4A shows the 300 most regulated genes in response to
Sunitinib treatment (FDR,0.001). Clearly, the samples are nicely
separated into treated vs. untreated samples. However, the
pronounced stripes in the heat map indicate that the majority of
genes change expression only in subsets of cases. This result is well
expected given the heterogeneous response of the pathways that
ultimately shape these expression profiles.
Gene expression profiles of treated but not of untreated
BTIC lines predict proliferation
We proceeded to develop gene expression signatures to predict
proliferation 96 hours after treatment. We derived these signatures
from (a) expression levels prior to treatment and (b) expression
levels 6 hours after treatment. Our signatures did not only aim to
distinguish responders from non-responders (classification) but
aimed to predict the XXT assay based proliferation rates
quantitatively (regression). We used least angle regression [38] to
simultaneously identify a set of signature genes, the optimal
number of signature genes, and weights for the chosen genes.
Proliferation 96 hours after treatment was predicted using the
resulting weighted average of expression of the identified genes.
Predictions were done in leave one out cross validation.
Importantly, gene selection was done for every left out sample
separately to avoid overly optimistic results due to overfitting. The
x-axis shows cross-validated predictions of proliferation response
after 96 hours based on gene expression levels monitored 6 hours
after treatment, while the y-axis shows the actual proliferation
measurements after 96 hours. The correlation between predicted
and measured proliferation is significant (p,0.01, chi-square test)
(Fig. 2D). When using the complete data set without leaving out
samples the same algorithm identifies a 6-gene signature (CLK4,
BCLAF1, LOC100130581, ACTG2, VAV3, DPF3) that can be
used to predict proliferation of BTIC lines in independent samples.
Hence, early expression changes in response to treatment
forecast long-term functional responses. In contrast, we were not
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able to predict proliferation from expression data that was
recorded prior to treatment using the exact same statistical
analysis strategy (p= 0.98; Fig. 2E.). In addition we did not
observe any correlation between in vitro response and the strength
of signaling modulation after treatment that was analyzed
concurrently with gene expression profiles (Fig. S5). Consequently,
semi-quantitative Western blot analysis of a selected panel of
signaling transmitter molecules did not provide any information
for the prediction of treatment effects.
To verify the gene expression levels of the 6 signature genes
measured with microarray, we assessed the expression levels in 6 of
the BTIC lines by qPCR analysis (Fig. 4B). The qPCR results
confirmed that the directions of regulation were consistent with
those observed by microarray analysis. We used b-Actin normal-
ized expression values. Fig. 4B shows that the observed log fold
changes were well reproduced for (5/6) signature genes using
qPCR. The exception is ACTG2. Of note, ACTG2 has the
smallest weight of all genes in the signature. Its weight is 3 orders
of magnitude smaller then e.g. the weight of DPF3 (data not
shown). In summary, prediction of proliferation response is
possible. However, BTIC lines had to be confronted with the
drug to make them release predictive information.
Gene expression profiles of treated and untreated BTIC
lines do not predict migration
Since inhibition of proliferation did not correlate with inhibition
of cellular motility, we aimed to develop a different gene
expression signature to predict motility. Using the same statistical
strategy as described under proliferation prediction, we could not
identify a gene signature that predicted migration after a 16 hours
incubation period (Fig. 3D, E).
Discussion
In vitro drug testing tools for predicting treatment effects in
tumor patients were undertaken for more than 30 years. None of
them has reached clinical application. Limitations lay in the long-
term culture of differentiated tumor cell lines with prolonged
treatment periods and conventional assays as readout. It is well
known that tumor lines propagated under serum-containing
Figure 2. Cellular growth and proliferation under Sunitinib treatment. BTICs were incubated with 1 mM Sunitinib or 0.00025% DMSO
(control), and the XTT proliferation assay was performed after 96 h. Each individual assay was performed with five replicates per treatment group. The
assay was repeated at least three times for each cell line. (A) Growth pattern in a responding (BTIC-5) and a non-responding (BTIC-16) BTIC line.
Representative pictures are shown for two differently responding BTIC lines. (B) The mean absorbance of Sunitinib treated cells relative to control
cells obtained in an individual assay was assessed after 24 h, 96 h and 144 hours incubation period and is plotted in a dot blot graph (y-axis) against
incubation time (x-axis). (C) The relative difference of the mean proliferation relative to control is blotted in a dot blot graph (y-axis) against the
corresponding BTIC line (x-axis). Each data point indicates the result of an individual experiment. The assay shows the variety of effects in the
investigated lines. (D) Prediction of proliferation based on gene expression 6 h after treatment in vivo. The x-axis shows cross validated predictions of
proliferation response after 96 hours based on gene expression levels monitored 6 hours after treatment, while the y-axis shows the actual
proliferation measurements after 96 hours. The correlation between predicted and measured proliferation is significant (p,0.01, chi-square test). (E)
Failed prediction of proliferation using expression values from untreated samples. There is no significant correlation between predictions and
measurements (p = 0.98).
doi:10.1371/journal.pone.0108632.g002
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Figure 3. Migration under Sunitinib examined by multicellular spheroid expansion assay. Spheroids were incubated with 1 mM Sunitinib
or 0.00025% DMSO (control) in a round-bottomed 96 well plate. Radial expansion of BTICs from the spheroid was recorded after 16 hours incubation.
(A) Representative pictures of two differently responding BTIC lines (BTIC-2 and BTIC-3) show different patterns of migration. (B) The relative
difference of the mean covered area relative to control is blotted in a dot blot graph (y-axis) against the corresponding BTIC line (x-axis). (C) The mean
spheroid size relative to control (y-axis) is blotted against the corresponding relative proliferation inhibition (x-axis) for each of the 18 BTIC lines. (D)
Failed prediction of migration on gene expression 6 h after treatment in vivo. The x-axis shows cross validated predictions of migration, while the y-
axis shows the actual migration measurements. There is no significant correlation between predictions and measurements (p = 0.287). (E) Failed
prediction of migration using expression values from untreated samples. There is no significant correlation between predictions and measurements
(p = 0.179).
doi:10.1371/journal.pone.0108632.g003
Figure 4. Heterogeneity of expression response to Sunitinib treatment. (A) Shown is a heat map of the 300 most differentially expressed
genes when comparing Sunitinib treated with untreated samples. The samples are nicely separated into treated vs. untreated samples. However, the
pronounced stripes in the heat map indicate that the vast majority of genes change expression only in subsets of cases. (B) The mean logFCs
between control and Sunitinib treated samples for the predictive genes (CLK4, BCLAF1, LOC100130581, ACTG2, VAV3, DPF3) of 6 BTIC lines was
calculated using (i) Microarray data and (ii) b-Actin normalized expression values assessed by qPCR for each individual gene.
doi:10.1371/journal.pone.0108632.g004
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conditions exert alterations in their molecular phenotype [43].
Additionally, the use of serum additives induces ex vivo modifi-
cations of functional behavior making valuable results unlikely.
Finally, treatment response prediction before in vivo treatment
was not assessed up to now using -omics technologies. To
approach this, we first used serum-free short-term cultures of
freshly resected high-grade gliomas; second, we performed short-
term treatment with Sunitinib in a dose correlating to in vivo drug
levels; and third, we monitored the response of thousands of
molecular variables assessed by a microarray to define a genetic
pattern of response.
We show that a gene signature deduced from microarray can
predict inhibition of proliferation by Sunitinib in short-term
serum-free cultures of brain tumor initiating cells (BTIC). In
contrast the transcriptomes prior to treatment did not allow for the
prediction of treatment response explaining the failure of previous
attempts to establish predictive gene expression signatures in the
field of glioma.
It is important to note that our signature is truly predictive. We
monitored gene expression 6 hours after start of treatment.
Considering an average cell cycle time of around 20 hours, we
therefore forecast proliferation inhibition detected 96 hours after
treatment from observations recorded only 6 hours after
treatment. Interestingly, not the activation of individual pathways
assessed by Western blots but the gene expression signature
identified by microarrays allowed the prediction of treatment
response. We therefore speculate that multiple alternative pathway
activation constellations can lead to the same downstream result:
the typical expression signature we observed if treatment impaired
proliferation.
Tumor growth, progression and metastasis are partly mediated
by activated receptor tyrosine kinases [44]. Complex signaling
cross-talks between different growth-factor cascades regulate the
self renewal and invasive capacity of BTICs [45]. Sunitinib inhibits
selective VEGF/PDGF-stimulated activation of STAT3, AKT
and ERK1/2 in BTIC cultures. Interestingly, we observed
heterogeneous modulation of phosphorylation when Sunitinib
was compared to control treatment with and without exogenous
VEGF/PDGF stimulation. Tumor cells acquire genomic alter-
ations that greatly reduce their dependency on exogenous growth
stimulation, conserving their proliferation, survival and motility
[46,47]. In our assays, we did not notice any morphological
changes that would indicate differentiation during culture in
VEGF/PDGF restricted medium, and we proved that PDGF/
VEGF preserves constant proliferation capacity of BTICs.
Therefore we are confident that our experimental conditions
allow the detection of the maximum effect of Sunitinib on essential
signaling pathways and presumably also on transcription.
The intracellular signaling network is highly complex and an
analysis of signaling pathway modulation can only provide a small
insight. This may be one reason that particular transmitters cannot
predict functional effects in vitro. As an example, it has been
reported that short-term treatment with Sunitinib induces the
expression of the dual lipid and phosphatase PTEN that negatively
regulates PI3K/AKT [12], whereas at long-term exposure induces
epigenetic silencing of the PTEN gene [48]. Therefore, regulation
of pAKT after 6 hours of treatment may differ from pAKT after
96 hours and thus may not predict impaired cell growth after 96
hours. This observation corresponds well to other findings in the
literature. Yang et al. [10] showed that phosphorylated ERK1/2
was not affected, but AKT and STAT3 phosphorylation was
substantially reduced in medulloblastoma cell lines after short-
term treatment with Sunitinib. Furthermore, in line with the
results of Zhou et al. [49], differences of pERK were not
statistically relevant to distinguish between Sunitinib sensitive and
resistant U87MG glioma xenograft tumors.
Cellular viability testing using the XTT-assay revealed that
BTICs differ according to their response to Sunitinib. This
corresponds well to clinical data where only a small subgroup of
patients with high-grade gliomas responded to treatment with
Suntininib. Only in a small subset of Sunitinib treated BTIC
cultures, we found a reduction of viable cells down to 56%
compared to control treatment. As we did not observe cytotoxic
short-term effects of 1 mM Sunitinib, the decrease of viable cells is
likely to be a consequence of a reduced proliferation rate. Here,
the correlation between predicted growth inhibition and measured
growth inhibition was highly significant. Inhibition of cellular
growth at clinically relevant concentrations observed in other
studies using in vitro models are comparable to those detected in
our study [11,13,14].
Concerning our migration assays, a steep onset of migration and
a halted volumetric growth of spheroids during the first 24 hours
has been published elsewhere [50]. Therefore, the contribution of
proliferation in this experimental setup can probably be neglected.
The effect of Sunitinib on migration was independent of the BTIC
line specific motility and again very heterogeneous among the
whole BTIC panel.
Based on our results, we suggest a novel design for predictive
gene expression studies. We argue that it is important to ask the
right cells the right questions. Here, untreated bulk tumor cells
might not hold the necessary predictive information. Progenitor
cells selected by short-term in vitro culture and treated over short
periods of time, in contrast, show patterns of treatment response.
We can only speculate why only expression signatures after
treatment hold prognostic information. If the response is not
stochastic, there must be a molecular difference between the two
cell types, most likely genetic or epigenetic modifications, that alter
the way incoming signals (treatment) are processed by the cells.
This difference may only be reflected in expression profiles after
challenging the cells with treatment, as they only then activate a
defence response, which then leaves traces in gene expression
profiles. In vitro cultures are a valid tool to confront cells with an
agent before expression profiling. Our preclinical study shows that
this strategy yields information that is not accessible from biopsy
profiles. While this does not proof that our strategy will be useful in
clinical trails, it is encouraging as a first development step.
Supporting Information
Figure S1 Comparison of proliferation regulation with
XTT-assay against BrdU incorporation assay. Prolifera-
tion assays was performed as described earlier. Cells were treated
with 0.2 mM, 1 mM Sunitinib or 0.00025% DMSO for 120 hours.
For both assays the mean absorbance of Sunitinib treated cells
relative to control cells were calculated and depicted as bar graphs.
Almost identical results were obtained with XTT-Assay and BrdU
incorporation assay for the two representative cell lines BTIC-1
and BTIC-2.
(TIF)
Figure S2 Comparison of BTIC proliferation with
different growth factor supplementation. Proliferation
assays were performed as described in the material and methods
section. Media containing 25 ng/ml of each bFGF and EGF or
25 ng/ml of each VEGF and PDGF-AB was added instead of
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treatment. The XTT proliferation assay was evaluated after 48,
96, and 144 hours. No significant difference of proliferation could
be shown at 48 and 144 hours cultivation under defined conditions
(p = 0.056 and 0.1, respectively).
(TIF)
Figure S3 Verification of the spheroid expansion assay
with the in vitro scratch assay. Scratch migration assays
were performed as described above with 1 mM Sunitinib or
0.00025% DMSO for 24 hours. (A) Sunitinib induced a significant
decrease of migration in comparison to controls. (B) No significant
difference of inhibition of migration could be shown in spheroid
vs. scratch assays, verifying spheroid assay results (p = 0.116).
(TIF)
Figure S4 Correction for BTIC line specific expression
variances enables the detection of treatment specific
expression variances. (A) The 500 most variable genes were
hierarchically clustered according to Euclidean distances showing
that all treatment samples cluster within the corresponding BTIC
line. (B) After compensation for inter-tumoral variability using the
batch effect correction algorithm Combat samples clustered mainly
within treatment specific groups.
(TIF)
Figure S5 Mitogenic signaling modulation does not
correlate to proliferation or migration inhibition after
treatment. For each BTIC line XTT absorbance relative to
control (A, B, C) or the Spheroid size relative to control (D, E, F) is
plotted against the semi-quantitative consensus strength of
phosphorylation specific Western blot signals for one of the 3
(AKT, ERK, STAT3) signaling molecules. None of the phos-
phorylation levels of the signal transducers correlated to inhibition
of proliferation or migration.
(TIF)
Table S1 Clinical and biological information of paren-
tal tumor specimen from the analyzed BTIC panel vs.
BTIC lines. Histology and WHO tumor grade were evaluated in
the original tumors by an independent neuropathologist (MR).
MGMT=Methyl-Guanine-Methyl-Transferase; meth. =methy-
lated MGMT-Promotor (.8%); unmeth. = unmethylated
MGMT-Promotor; IDH= isocitrate dehydrogenase; wt =wild
type; n.d. = not determined; f = female; m=male; R=Radiother-
apy 60 Gy; RC=Radiotherapy 60 Gy plus Chemotherapy with
Temozolomide 75 mg/m2 daily during radiotherapy, then
adjuvant Temozolomide 150–200 mg/m2 d1-5/28 days (Stupp
protocol).
(DOCX)
Table S2 RT-PCR primer sequences. Primers for the 6-
gene signature set (CLK4, BCLAF1, LOC100130581, ACTG2,
VAV3, DPF3) that can be used to predict proliferation of BTIC
lines in independent samples are given.
(DOCX)
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